Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

NCT01954784 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Funding unavailable

Conditions

Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions

DRUG: fludarabine phosphate
RADIATION: total-body irradiation
PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation
DRUG: cyclosporine
DRUG: mycophenolate mofetil
DRUG: bortezomib
DRUG: lenalidomide
OTHER: laboratory biomarker analysis

Sponsor

Case Comprehensive Cancer Center

Collaborators

[object Object]